Chongqing Lummy Stock Soars 8.46%, Hits Intraday High of CNY 5.55

Chongqing Lummy Pharmaceutical Co., Ltd. has experienced a significant uptick in its stock performance, gaining 8.46% on June 30, 2026. The stock reached an intraday high of CNY 5.55, marking a notable achievement for the small-cap company within the pharmaceuticals and biotechnology sector. In terms of performance metrics, Chongqing Lummy has outperformed the China Shanghai Composite index, which recorded a modest gain of 0.5% on the same day. Over the past week, the company has shown a robust increase of 7.77%, contrasting with the Shanghai Composite's decline of 0.29%. However, the stock's performance over the past month reflects a decrease of 4.11%, while its year-to-date performance stands at a slight decline of 0.19%. Despite these recent gains, the company faces challenges, including a low return on capital employed and a history of negative net profit. The market capitalization of Chongqing Lummy is currently CNY 4,053 million, indicating its position as a small-cap player in a competitive industry.